Project Grant R01AG098878
Award Date 9/15/26
Completion Date 6/30/31
Dollars Obligated $739K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Irvine, CA 92697, USA
Similar Awards
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $356,174 to The Regents of the University of California, San Francisco (UCSF) to conduct in vivo testing of structure-based vaccine candidates targeting Alzheimer's disease. The goal is to determine the efficacy of an active immunization strategy in preserving cognitive and neural function by slowing the formation of amyloid-beta or tau protein aggregation in the brain. The research will use...
- The National Institute on Aging awarded the University of California, Los Angeles $126,063 on August 5, 2026, under the Aging Research program (CFDA 93.866) to determine the atomic structures of amyloid-beta and tau oligomers and to characterize the molecular interaction between amyloid-beta and the TREM2 receptor on microglia. The award is classified as a Project Grant, specifically a K99/R00 award. The research develops a novel oligomer structure determination pipeline incorporating native...
- The National Institute on Aging awarded the University of California Irvine $636,124 for Project Grant R01AG100345 on September 2, 2026, under the Aging Research program (CFDA 93.866). The award funds multi-omic characterization of molecular pathways driving vulnerability and resilience to Alzheimer's disease in the oldest-old population (age 90 and above). The research employs an integrative multi-omic approach including single-nucleus RNA and ATAC sequencing, spatial transcriptomics, and...
- The National Institute on Aging, part of the Department of Health and Human Services, awarded the University of California, Los Angeles $146,750 under the Aging Research program (CFDA 93.866) on July 1, 2026, to identify molecular-neuropathological signatures in Alzheimer's disease, frontotemporal lobar degeneration, and long COVID. The recipient will employ single-cell spatial multi-omics on postmortem brain tissues to characterize molecular and cellular alterations linked to selective...
- The National Institute on Aging, part of the Department of Health and Human Services National Institutes of Health, awarded $442,750 to the University of California, Davis on September 1, 2026, under the Aging Research program (CFDA 93.866, assistance type: Project Grant) to investigate galectin-12's role in neuroinflammation and Alzheimer's disease progression. The funded research examines how metabolic stress triggers Alzheimer's disease by enhancing inflammation, with a focus on lipid droplet...
- The National Institute on Aging, a division of the Department of Health and Human Services National Institutes of Health, awarded Advantage Therapeutics, Inc. $3.749 million on September 20, 2025, under the Aging Research program (CFDA 93.866) to perform IND-enabling studies on a small-molecule immunomodulating compound for Alzheimer's disease. The recipient will conduct preclinical and IND-enabling studies on a disease-modifying therapeutic designed to reduce brain inflammation and restore...
- The National Institute on Aging awarded the University of Virginia $583,815 on August 15, 2026, under the Aging Research program (CFDA 93.866) to support research into oligodendrocyte lineage dysfunction during aging and Alzheimer's disease. The project aims to understand how myelin loss—a pathology common to both aging and Alzheimer's disease—develops in the central nervous system and to identify therapeutic targets for cognitive impairment. The research focuses on oligodendrocyte precursor...
- The National Institute on Aging awarded the University of California, Berkeley $549,260 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop advanced large language model-based AI tools that enhance precision in predicting Alzheimer's disease pathology and cognitive outcomes. The research addresses critical gaps in precision medicine for Alzheimer's disease, particularly the need to capture patient heterogeneity, accurately identify treatment candidates for...
- The National Institute on Aging awarded the University of California, San Diego $408,012 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop methods for improving central nervous system pharmacokinetics of targeted protein degraders through specialized assay workflows and prodrug chemistries. The research will establish dual-functional molecules that hijack endogenous molecular transport pathways to cross the blood-brain barrier, with early-stage application to...
- The National Institute on Aging awarded New York University $712,578 on February 1, 2026, under the Aging Research program (CFDA 93.866) to conduct a prospective study identifying viral infections associated with cognition decline and Alzheimer's disease risk across three prospective cohorts. The award supports comprehensive serologic profiling using VirScan, a bacteriophage immunoprecipitation sequencing technology, to detect immune responses to human viruses and analyze antiviral antibodies in...